Decoding Dementia: How AI is Transforming Brain Diagnostics in Asia

SINGAPORE – July 02, 2026 – A landmark agreement between South Korean AI firm Neurophet and Singapore’s Raffles Medical Group is set to deploy a powerful new diagnostic tool across Southeast Asia, marking a pivotal moment in the region's fight against neurodegenerative diseases. The partnership brings Neurophet AQUA, an AI-powered brain imaging analysis software, into Raffles Medical’s vast network of over 100 clinics, promising to accelerate and refine the diagnosis of conditions like Alzheimer's disease, vascular dementia, and Multiple Sclerosis.

This collaboration is more than a simple technology transfer; it represents a strategic investment in the future of neurological care. For Raffles Medical, it’s an enhancement of its diagnostic arsenal, integrating cutting-edge technology to improve patient outcomes. For Neurophet, it’s a significant expansion into the dynamic Asian healthcare market, building on prior collaborations with leading Singaporean research institutions. At its core, this partnership underscores a fundamental shift in how we approach brain health, moving from subjective assessment to data-driven, quantitative analysis.

The Innovation Engine: Precision and Speed in Neuroimaging

The true innovation behind this partnership lies in the capabilities of Neurophet AQUA. Traditional analysis of brain MRI scans is a meticulous, time-consuming process, often taking hours of a radiologist's valuable time and relying on visual interpretation to spot subtle changes. Neurophet AQUA automates and quantifies this process, delivering a comprehensive analysis in approximately five minutes.

The software uses advanced AI algorithms to segment the brain into distinct anatomical regions, measure their volume, and detect and quantify abnormalities like brain atrophy or white matter hyperintensities—key biomarkers for neurodegenerative diseases. This provides clinicians with objective, numerical data that can be compared against normative databases tailored for both Asian and Western populations, removing ambiguity and enabling a more precise diagnosis.

The clinical efficacy of this technology is not just theoretical. A recent prospective study conducted at Singapore’s Nanyang Technological University, published in September 2025, validated Neurophet AQUA’s performance within a Southeast Asian cohort. The findings demonstrated a strong correlation between the AI's analysis and assessments by expert clinicians, confirming its ability to accurately differentiate between healthy individuals, those with mild cognitive impairment, and patients with dementia. Furthermore, a multi-center evaluation published in late 2025 found the software’s segmentation quality comparable to established research tools like FreeSurfer, but with a dramatically faster processing time, a crucial advantage in busy clinical settings.

This robust validation, coupled with a string of regulatory approvals—including multiple FDA 510(k) clearances in the U.S., CE marking in Europe, and approvals in Japan, Korea, and Singapore—cements Neurophet AQUA's position as a trusted, world-class medical device. Specialized modules, such as Neurophet AQUA MS for Multiple Sclerosis and Neurophet AQUA AD Plus for Alzheimer's, further tailor the platform's power to specific disease states, supporting everything from initial diagnosis to monitoring the effects of new anti-amyloid drug treatments.

A Strategic Alliance for a Healthier Future

The agreement is a calculated move for both organizations, reflecting broader trends in global healthcare. For Neurophet, a company founded in 2016 with the mission of pioneering AI-based solutions for brain disorders, this partnership is a major foothold in one of the world's fastest-growing healthcare markets. As Co-CEO Jake Junkil Been stated, "We are very pleased to supply Neurophet's products to Raffles Medical, following collaborations with public institutions such as the Dementia Research Centre at Nanyang Technological University, National University of Singapore, and Singapore General Hospital."

This move builds on a foundation of research and establishes a significant clinical reference point in the region. It positions the company to compete effectively against other global players in the neuroimaging AI space by demonstrating its technology's real-world value in a premier healthcare system.

For Raffles Medical Group, adopting Neurophet AQUA aligns perfectly with Singapore’s national strategy to become a leading digital health hub. It signals a deep commitment to institutional innovation and providing patients with access to the most advanced diagnostic technologies available. By empowering its clinicians with AI, Raffles Medical can enhance workflow efficiency, reduce diagnostic uncertainty, and ultimately deliver a higher standard of care. This proactive integration of AI is a clear indicator of the group's forward-thinking approach to medicine, where technology is a key enabler of better health outcomes.

Redefining Patient Care in an Aging Population

Beyond the business and technology, the most profound impact of this partnership will be felt by patients and their families. Southeast Asia, like much of the world, is facing the mounting challenge of an aging population and a corresponding rise in the prevalence of neurodegenerative diseases. The journey to a dementia diagnosis is often long and fraught with uncertainty, a period of anxiety for individuals and their loved ones. Traditional methods can miss the earliest signs of disease, delaying access to supportive care and potential treatments when they are most effective.

Tools like Neurophet AQUA have the potential to fundamentally change this trajectory. By providing a rapid, objective, and early assessment of brain health, the technology empowers doctors to intervene sooner and with greater confidence. The ability to track disease progression quantitatively over time offers an invaluable guide for managing treatment and personalizing care plans. This shift toward early and precise diagnostics is not just an incremental improvement; it is a vital step toward mitigating the immense societal and personal costs of these devastating diseases. As healthcare systems across the region grapple with this challenge, the fusion of clinical expertise and artificial intelligence represents our most promising path forward.